MedWatch

Life science heads Danish R&D efforts

Despite being the industry with the highest amount of spending on research and development in the country, sales of novel, patented drugs only account for a fraction of total sales for Danish life science companies, and that is a huge problem, says The Danish Association of the Pharmaceutical Industry (LIF).

Foto: NDAHL TORBEN

Danish life science is the industry that puts the largest amount of funds into research and development measured by net-turnover. The biotech, pharmaceutical and medtech industries spend 20.9 %, 14.8 % and 6.1 % respectively of their net-turnover on R&D, which puts them way ahead of other industries in Denmark.

The figures are taken from a memo from LIF, which also highlights the problem with patented products only making up 10 % of turnover.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier